Cerity Partners LLC Purchases 7,068 Shares of Eli Lilly and Company $LLY

Cerity Partners LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 607,198 shares of the company’s stock after purchasing an additional 7,068 shares during the quarter. Eli Lilly and Company comprises about 0.8% of Cerity Partners LLC’s holdings, making the stock its 19th biggest holding. Cerity Partners LLC owned 0.06% of Eli Lilly and Company worth $471,870,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Braun Bostich & Associates Inc. increased its position in shares of Eli Lilly and Company by 2.5% during the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after acquiring an additional 13 shares in the last quarter. Rise Advisors LLC boosted its stake in Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares during the last quarter. Occidental Asset Management LLC boosted its stake in Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after purchasing an additional 13 shares during the last quarter. New Insight Wealth Advisors increased its holdings in shares of Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after purchasing an additional 13 shares in the last quarter. Finally, Dash Acquisitions Inc. raised its stake in shares of Eli Lilly and Company by 2.8% in the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after purchasing an additional 13 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on LLY shares. Weiss Ratings raised Eli Lilly and Company from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Daiwa Capital Markets raised their price target on shares of Eli Lilly and Company from $700.00 to $940.00 in a report on Monday, November 10th. Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research note on Tuesday, December 2nd. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,087.32.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,009.26 on Friday. The company has a 50-day moving average price of $918.84 and a 200-day moving average price of $809.74. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $954.13 billion, a P/E ratio of 49.38, a PEG ratio of 1.12 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the business posted $1.18 earnings per share. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.